We aimed to study the vascular outcomes in hemodialysis (HD) patients based on their diabetic status. A cohort observational study was conducted among patients undergoing regular HD with a 5-year follow-up. Of the 252 consecutive HD patients, 60% were diabetic. Compared with nondiabetics, diabetics were 11 years older, 4 years lesser on HD, and more likely to have prior cerebrovascular and coronary artery disease (CAD). Overall 5-year follow-up showed that diabetic patients had higher rates of HD vascular accesses (57% vs 41%, P = .01), CAD (64% vs 33%, P = .001), major amputations (8.6% vs 0%, P = .003), and mortality (66% vs 23%, P = .001). On multivariate analysis, independent predictors of mortality included number of vascular accesses in nondiabetics and HD duration, CAD, and peripheral artery disease in diabetic patients. Diabetes mellitus is associated with a significant vascular burden and mortality among HD patients. Moreover, our finding highlights the vascular impact of renal failure and HD.
PanzettaGBasileCSantoroA. Diabetics on dialysis in Italy: a nationwide epidemiological study. Nephrol Dial Transplant. 2008;23(12):3988–3995.
2.
US Renal Data System: 2002Annual Data Report. Bethesda, MD: The National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 2002. http://www.usrds.org/adr.aspx. Accessed January 1, 2013.
3.
LocatelliFPozzoniPDel VecchioL. Renal replacement therapy in patients with diabetes and end-stage renal disease. J Am Soc Nephrol. 2004;15
(suppl 1):S25–S29.
BenerAZirieMJanahiIMAl-HamaqAOMusallamMWarehamNJ. Prevalence of diagnosed and undiagnosed diabetes mellitus and its risk factors in a population-based study of Qatar. Diabetes Res Clin Pract. 2009;84(1):99–106.
6.
WilburKAl AmeriM. An inventory of diabetes care in Qatar. Practical Diabetes Int. 2011;28(1):35–36.
7.
WoredekalY. Early detection and treatment of diabetic nephropathy. Pediatr Endocrinol Rev. 2008;5
(suppl 4):999–1004.
8.
Kalantar-ZadehKDeroseSFNicholasSBennerDSharmaKKovesdyCP. Burnt-out diabetes: impact of chronic kidney disease progression on the natural course of diabetes mellitus. J Ren Nutr. 2009;19
(1):33–37.
9.
HalimiSZmirouDBenhamouPY. Huge progression of diabetes prevalence and incidence among dialysed patients in mainland France and overseas French territories. A second national survey six years apart (UREMIDIAB 2 study). Diabetes Metab. 1999;25
(6):507–512.
10.
HollenbergNK. Higher incidence of diabetic nephropathy in type 2 than in type 1 diabetes in early-onset diabetes in Japan. Curr Hypertens Rep. 2001;3
(3):177.
11.
EarleKAPorterKKOstbergJYudkinJS. Variation in the progression of diabetic nephropathy according to racial origin. Nephrol Dial Transplant. 2001;16
(2):286–290.
12.
SattarAArgyropoulosCWeissfeldL. All-cause and cause-specific mortality associated with diabetes in prevalent hemodialysis patients. BMC Nephrology. 2012;13:130.
13.
StackAGBloembergenWE. Prevalence and clinical correlates of coronary artery disease among new dialysis patients in the United States: a cross-sectional study. J Am Soc Nephrol. 2001;12
(7):1516–1523.
14.
EggersPWGohdesDPughJ. Nontraumatic lower extremity amputations in the Medicare end-stage renal disease population. Kidney Int. 1999;56
(4):1524–1533.
15.
SchomigMRitzEStandlE. The diabetic foot in the dialyzed patient. J Am Soc Nephrol. 2000;11
(6):1153–1159.
16.
van DijkPCJagerKJZwindermanAHZoccaliCDekkerFW. The analysis of survival data in nephrology: basic concepts and methods of cox regression. Kidney Int. 2008;74
(6):705–709.
17.
BrownleeM. Glycation products and the pathogenesis of diabetic complications. Diabetes Care. 1992;15(12):1835–1843.
18.
YamagishiSMatsuiTNakamuraK. Olmesartan blocks inflammatory reactions in endothelial cells evoked by advanced glycation end products by suppressing generation of reactive oxygen species. Ophthalmic Res. 2008;40
(1):10–15.
19.
Al ThaniHEl-MenyarAHusseinA. Prevalence, predictors, and impact of peripheral arterial disease in hemodialysis patients: a cohort study with a 3-year follow-up. Angiology. 2013;64(2):98–104.
20.
ShigidiMMRamachandiranGRashedAHFituriOM. Demographic data and hemodialysis population dynamics in Qatar: a five year survey. Saudi J Kidney Dis Transpl. 2009;20(3):493–500.
21.
HouFJiangJChenJ. China collaborative study on dialysis: a multi-centers cohort study on cardiovascular diseases in patients on maintenance dialysis. BMC Nephrol. 2012;13:94.
22.
HerzogCAMaJZCollinsAJ. Poor long-term survival after acute myocardial infarction among patients on long-term dialysis. N Engl J Med. 1998;339(12):799–805.
23.
KraneVHeinrichFMeesmannM. German Diabetes and Dialysis Study Investigators. Electrocardiography and Outcome in Patients with Diabetes Mellitus on Maintenance Hemodialysis. Clin J Am Soc Nephrol. 2009;4
(2):394–400.
24.
NdipARutterMKVileikyteL. Dialysis treatment is an independent risk factor for foot ulceration in patients with diabetes and stage 4 or 5 chronic kidney disease. Diabetes Care. 2010;33(8):1811–1816.
25.
GameFLChipchaseSYHubbardRBurdenRPJeffcoateWJ. Temporal association between the incidence of foot ulceration and the start of dialysis in diabetes mellitus. Nephrol Dial Transplant. 2006;21
(11):3207–3210.
26.
HillMNFeldmanHIHiltonSCHolechekMJYlitaloMBenedictGW. Risk of foot complications in long-term diabetic patients with and without ESRD: a preliminary study. ANNA J. 1996;23
(4):381–388.
27.
BeckertSSundermannKWolfSKonigsrainerACoerperS. Haemodialysis is associated with changes in cutaneous microcirculation in diabetes mellitus. Diabet Med. 2009;26
(1):89–92.
28.
Tomaszuk-KazberukABachorzewska-GajewskaHMalyszkoJMalyszkoJMysliwiecMMusialWJ. Impact of diabetes mellitus on survival in patients with end-stage renal disease: a three-year follow-up. Kidney Blood Press Res. 2011;34(2):83–86.
29.
LokCEOliverMJRothwellDMHuxJE. The growing volume of diabetes-related dialysis: a population based study. Nephrol Dial Transplant. 2004;19(12):3098–3103.
30.
HayashinoYFukuharaSAkibaT. Diabetes, glycaemic control and mortality risk in patients on haemodialysis: the Japan dialysis outcomes and practice pattern study. Diabetologia. 2007;50
(6):1170–1177.
31.
VillarERemontetLLabeeuwMEcochardR. Effect of age, gender, and diabetes on excess death in end-stage renal failure. J Am Soc Nephrol. 2007;18(7):2125–2134.
32.
van DijkPCJagerKJStengelBGrönhagen-RiskaCFeestTGBriggsJD. Renal replacement therapy for diabetic end-stage renal disease: data from 10 registries in Europe (1991-2000). Kidney Int. 2005;67(4):1489–1499.
33.
SikoleANikolovVDzekovaP. Survival of patients on maintenance haemodialysis over a twenty-year period. Prilozi. 2007;28(2):99–110.
34.
NarayanKMBoyleJPThompsonTJSorensenSWWilliamsonDF. Lifetime risk for diabetes mellitus in the United States. J Am Med Assoc. 2003;290
(14):1884–1890.
35.
DisneyAPSRussGRWalkerRSheilAGR, eds. ANZDATA Registry Report 1997. Adelaide, South Australia: Australia and New Zealand Dialysis and Transplant Registry; 1998. http://www.anzdata.org.au/v1/annual_reports_download.html. Accessed 1 July 2013.
36.
KikkawaRKidaYHanedaM. Nephropathy in type II diabetes—epidemiological issues as viewed from Japan. Nephrol Dial Transplant. 1998;13
(11):2743–2745.
37.
RodríguézJAClèriesMVelaE. Diabetic patients on renal replacement therapy: analysis of catalan registry data. Renal registry committee. Nephrol Dial Transplant. 1997;12(12):2501–2509.
38.
KonnerKHulbert-ShearonTERoysECPortFK. Tailoring the initial vascular access for dialysis patients. Kidney Int. 2002;62
(1):329–338.
39.
YeagerRAMonetaGLEdwardsJM. Relationship of hemodialysis access to finger gangrene in patients with end-stage renal disease. J Vasc Surg. 2002;36
(2):245–249.
40.
FellströmBHoldaasHJardineAG. Cardiovascular disease in patients with renal disease: the role of statins. Curr Med Res Opin. 2009;25(1):271–285.
41.
BaigentCLandrayMJReithC. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet. 2011;377(9784):2181–2192.
42.
FellströmBCJardineAGSchmiederRE; AURORA study group. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med. 2009;360(14):1395–1407.
43.
AthyrosVGMikhailidisDP. Pharmacotherapy: statins and new-onset diabetes mellitus—a matter for debate. Nat Rev Endocrinol. 2012;8(3):133–134.
